



ThermoGenesis Provides Master File for the AutoXpress™ System to the FDA

New system automates the isolation and capture of cell populations from blood in a closed, sterile environment

RANCHO CORDOVA, Calif., October, 12, 2005 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (NASDAQ:KOOL) announced today that it has provided a Master File on the AutoXpress System to the FDA. The Master File summarizes pertinent information on the construction and operation of the AutoXpress System device and companion sterile blood processing disposable.

The purpose of the Master File is to assist those institutions that wish to utilize the AutoXpress System for the isolation of cell populations which require FDA permission for clinical use.

Per regulation, the Company intends to update the Master File as new pertinent information becomes available and will allow it to be cross referenced in other regulatory submissions, thus reducing the burden of duplicative reports and communications with the FDA.

The AutoXpress System, soon to begin customer testing, is a device and companion sterile closed blood processing disposable, designed to harvest the mononuclear cell population (including the hematopoietic stem and progenitor cells) from cord blood into a fixed volume of approximately 20 ml.

Regulatory Status: As cord blood is not currently an FDA licensed blood product, the company intends to convert and supplement the Master File into a formal application for marketing once the FDA licenses cord blood for clinical use.

About ThermoGenesis Corp.

ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics and surgical hemostasis. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood.

- The **BioArchive® System**, an automated robotic cryogenic device, is used by major cord blood stem cell banks in 26 countries as a key enabling technology for cryopreserving and archiving cord blood stem cell units for transplant.

- The **CryoSeal® FS System**, a semi-automated device and companion sterile blood processing disposable, is used to prepare hemostatic and adhesive surgical sealants from the patient's blood in about an hour. Enrollment in a 150 patient U.S. pivotal clinical trial has been completed and a PMA is being prepared.
- The **Thrombin Processing Device (TPD™)** is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of patient blood, or blood plasma in 25 minutes. The TPD market launch is underway in Europe.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. Source: ThermoGenesis Corp.

More Information, Contact:
THERMOGENESIS CORP.
Kevin Simpson: (916) 858-5100
Web site: <http://www.thermogenesis.com/>